Knott David M Jr Coherus Bio Sciences, Inc. Transaction History

Knott David M Jr

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$2.02 - $3.14 $848,656 - $1.32 Million	-420,127 Reduced 79.82%	106,185 $254,000
Q4 2023 Feb 13, 2024	SELL	$1.59 - $3.85 $164,863 - $399,198	-103,688 Reduced 16.46%	526,312 $1.75 Million
Q3 2023 Nov 13, 2023	BUY	$3.74 - $5.45 $1.44 Million - $2.1 Million	384,990 Added 157.13%	630,000 $2.36 Million
Q2 2023 Aug 11, 2023	BUY	$3.79 - $8.3 $928,587 - $2.03 Million	245,010 New	245,010 $1.05 Million
Q4 2022 Feb 13, 2023	SELL	$5.69 - $10.07 $406,738 - $719,833	-71,483 Reduced 35.74%	128,517 $1.02 Million
Q3 2022 Nov 10, 2022	BUY	$7.17 - $13.87 $99,419 - $192,321	13,866 Added 7.45%	200,000 $1.92 Million
Q2 2022 Aug 11, 2022	BUY	$5.86 - $13.23 $401,872 - $907,300	68,579 Added 58.34%	186,134 $1.35 Million
Q1 2022 May 16, 2022	BUY	$10.92 - $16.41 $163,800 - $246,150	15,000 Added 14.63%	117,555 $1.52 Million
Q4 2021 Feb 11, 2022	BUY	$15.81 - $18.99 $1.62 Million - $1.95 Million	102,555 New	102,555 $1.64 Million

137

78M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $96.4M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Knott David M Jr, based on Form 13F filings with the SEC.

Stay updated on Knott David M Jr with notifications on news.